Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008–2016

Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008–2016

Background Women with idiopathic pulmonary arterial hypertension (IPAH) have been found to have a worse haemodynamic status at diagnosis, but better survival than men. Over the past decade, demographics have changed and new treatments have become available. The objective of this study was to investi...

Bibliografski detalji
Glavni autori:	Barbro Kjellström, Magnus Nisell, David Kylhammar, Sven-Erik Bartfay, Bodil Ivarsson, Göran Rådegran, Clara Hjalmarsson
Format:	Članak
Jezik:	English
Izdano:	European Respiratory Society 2019-08-01
Serija:	ERJ Open Research
Online pristup:	http://openres.ersjournals.com/content/5/3/00075-2019.full

Slični predmeti

Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
od: Barbro Kjellström, i dr.
Izdano: (2020-12-01)

Predicting mortality during long-term follow-up in pulmonary arterial hypertension
od: David Kylhammar, i dr.
Izdano: (2021-05-01)

Coping, social support and information in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A 2-year retrospective cohort study
od: Bodil Ivarsson, i dr.
Izdano: (2018-01-01)

Everyday life experiences of spouses of patients who suffer from pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
od: Bodil Ivarsson, i dr.
Izdano: (2019-02-01)

Respiratory rate modulation improves symptoms in patients with pulmonary hypertension
od: Barbro Kjellström, i dr.
Izdano: (2021-10-01)

Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
od: Barbro Kjellström, i dr.
Izdano: (2022-10-01)

Change in health‐related quality of life at early follow‐up in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
od: Bodil Ivarsson, i dr.
Izdano: (2024-01-01)

The Odyssey from Symptom to Diagnosis of Pulmonary Hypertension from the Patients and Spouses Perspective
od: Bodil Ivarsson, i dr.
Izdano: (2021-07-01)

Prevalence of potential drug–drug interactions with disease‐specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A registry study
od: Puck N. Norell, i dr.
Izdano: (2022-07-01)

Outpatient specialist clinics for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the Nordic countries
od: Barbro Kjellström, i dr.
Izdano: (2020-10-01)

Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study
od: Clara Hjalmarsson, i dr.
Izdano: (2020-09-01)

Perceptions of Received Information, Social Support, and Coping in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
od: Bodil Ivarsson, i dr.
Izdano: (2014-01-01)

Perceptions of Received Information, Social Support, and Coping in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
od: Bodil Ivarsson, i dr.
Izdano: (2014-10-01)

Right ventricular dyssynchrony predicts outcome in pulmonary arterial hypertension when assessed in multiple cardiac magnetic resonance views
od: Anthony Lindholm, i dr.
Izdano: (2024-01-01)

Societal costs associated with pulmonary arterial hypertension: A study utilizing linked national registries
od: Hannes Runheim, i dr.
Izdano: (2023-01-01)

Societal costs associated to chronic thromboembolic pulmonary hypertension: A study utilizing linked national registries
od: Barbro Kjellström, i dr.
Izdano: (2023-04-01)

Left ventricular dysfunction in pulmonary arterial hypertension is attributed to underfilling rather than intrinsic myocardial disease: a CMR 2D phase contrast study
od: Ashwin Venkateshvaran, i dr.
Izdano: (2024-07-01)

Pulmonary Blood Volume Variation in Patients with Precapillary Pulmonary Hypertension
od: Mariam Al-Mashat, PhD, i dr.
Izdano: (2024-01-01)

Information Experiences and Needs in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
od: Bodil Ivarsson, i dr.
Izdano: (2014-01-01)

Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification
od: Habib Bouzina, i dr.
Izdano: (2020-06-01)

Structured evaluation of unclear dyspnea–An attempt to shorten the diagnostic delay in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
od: Salaheldin Ahmed, i dr.
Izdano: (2024-01-01)

Risk assessment in pulmonary arterial hypertension: A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
od: Abdulla Ahmed, i dr.
Izdano: (2023-04-01)

Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension
od: Habib Bouzina, i dr.
Izdano: (2018-11-01)

Association between central haemodynamics and renal function in advanced heart failure: a nationwide study from Sweden
od: Emanuele Bobbio, i dr.
Izdano: (2022-08-01)

The trajectory of renal function following mechanical circulatory support and subsequent heart transplantation
od: Sven‐Erik Bartfay, i dr.
Izdano: (2022-08-01)

Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
od: Abdulla Ahmed, i dr.
Izdano: (2021-10-01)

Higher plasma IL-6 and PTX3 are associated with worse survival in left heart failure with pulmonary hypertension
od: Sara Helleberg, i dr.
Izdano: (2022-08-01)

Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double‐Blind Controlled Trial
od: Lukas Lannemyr, i dr.
Izdano: (2018-08-01)

Sex differences in risk factors, treatment, and prognosis in acute stroke
od: Solveig Dahl, i dr.
Izdano: (2020-09-01)

Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
od: Mattias Arvidsson, i dr.
Izdano: (2019-12-01)

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
od: Mattias Arvidsson, i dr.
Izdano: (2021-04-01)

Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension
od: Habib Bouzina, i dr.
Izdano: (2019-12-01)

Risk assessment in pulmonary arterial hypertension patients with multiple comorbidities and/or advanced age—Where do we stand and what's next?
od: Abdulla Ahmed, i dr.
Izdano: (2023-10-01)

Sex hormones, CSF and serum leptin in patients with idiopathic intracranial hypertension
od: Mohamed Abdelghaffar, i dr.
Izdano: (2022-04-01)

Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
od: Niklas Bergh, i dr.
Izdano: (2020-04-01)

Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension
od: Salaheldin Ahmed, i dr.
Izdano: (2022-02-01)

Elevated plasma WIF‐1 levels are associated with worse prognosis in heart failure with pulmonary hypertension
od: Kriss Kania, i dr.
Izdano: (2022-12-01)

Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
od: Mattias Arvidsson, i dr.
Izdano: (2022-01-01)

Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
od: Joanna Säleby, i dr.
Izdano: (2019-11-01)

A novel echocardiographic right ventricular dysfunction score can identify hemodynamic severity profiles in left ventricular dysfunction
od: Odd Bech-Hanssen, i dr.
Izdano: (2022-08-01)